Breaking: Piper Jaffray Reiterates $60.0 PT On Aimmune Therapeutics (AIMT) Shares, Reiterates Their Original “Buy” Rating

March 18, 2018 - By Maria Brooks

 Breaking: Piper Jaffray Reiterates $60.0 PT On Aimmune Therapeutics (AIMT) Shares, Reiterates Their Original

Aimmune Therapeutics (AIMT) Rating Reaffirmed

Piper Jaffray now has a $60.0 target on shares of Aimmune Therapeutics (AIMT). The target indicates a potential upside of 89.57 % from the last stock price of Aimmune Therapeutics (AIMT). This rating was released in a note on Tuesday, 5 December.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Coverage

Among 9 analysts covering Aimmune Therap… (AIMT), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therap… has $80.0 highest and $30.0 lowest target. $58.13’s average target is 83.67% above currents $31.65 stock price. Aimmune Therap… had 31 analyst reports since March 7, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 23 by Wedbush. The rating was initiated by JMP Securities on Monday, September 26 with “Mkt Outperform”. On Wednesday, June 14 the stock rating was maintained by Wedbush with “Buy”. The company was maintained on Monday, October 23 by Credit Suisse. Wedbush maintained the stock with “Buy” rating in Monday, February 12 report. The company was maintained on Monday, March 5 by Roth Capital. As per Monday, March 5, the company rating was maintained by Credit Suisse. The firm has “Outperform” rating by Credit Suisse given on Monday, March 7. Piper Jaffray maintained the shares of AIMT in report on Friday, October 20 with “Buy” rating. The rating was maintained by Credit Suisse with “Buy” on Tuesday, July 18.

The stock decreased 2.01% or $0.65 during the last trading session, reaching $31.65. About 2.03 million shares traded or 115.90% up from the average. Aimmune Therapeutics, Inc. (AIMT) has risen 32.49% since March 18, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on May, 14. They expect $-0.67 earnings per share, down 28.85 % or $0.15 from last year’s $-0.52 per share. After $-0.81 actual earnings per share reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -17.28 % EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.83 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.